Wnt signaling pathway-targeted antitumor therapeutics in clinical translation: Advances and challenges
Current Pharmaceutical Analysis · 2026-06 · 22 (5) · 375-378
DOI: 10.1016/j.cpan.2026.03.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Pharmaceutical Analysis, 2026-06. Verfasst von Chen Xue und 2 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Development Fund, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Science and Technology Development Fund
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Xue, C., Zhu, D., & Li, L. (2026). Wnt signaling pathway-targeted antitumor therapeutics in clinical translation: Advances and challenges. Current Pharmaceutical Analysis, 22(5), 375-378. https://doi.org/10.1016/j.cpan.2026.03.009
Vancouver
Xue C, Zhu D, Li L. Wnt signaling pathway-targeted antitumor therapeutics in clinical translation: Advances and challenges. Current Pharmaceutical Analysis. 2026;22(5):375-378. doi:10.1016/j.cpan.2026.03.009
BibTeX
@article{Xue2026,
author = {Xue, Chen and Zhu, Danhua and Li, Lanjuan},
title = {Wnt signaling pathway-targeted antitumor therapeutics in clinical translation: Advances and challenges},
journal = {Current Pharmaceutical Analysis},
year = {2026},
volume = {22},
number = {5},
pages = {375--378},
doi = {10.1016/j.cpan.2026.03.009}
}
EUVIMED